Long-acting injectable innovations are shaping the Leqvio Market 2026

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

What Market Valuation Is Forecasted For The Leqvio Market By 2030 Starting From Its 2026 Size?

Historical growth stemmed from a rising incidence of hyperlipidemia, alongside advancements in RNA interference technology, the expansion of cardiovascular specialty clinics, growing awareness regarding LDL cholesterol management, and improved injectable drug delivery systems.

The expansion throughout the projected timeframe is largely driven by the increasing integration of innovative RNA-based treatments, a heightened concentration on mitigating cardiovascular risks, the proliferation of therapies with extended dosing intervals, growing financial commitments to cardiometabolic investigations, and an escalating need for enduring lipid-reducing solutions.

Significant developments anticipated during the forecast period include a surge in the utilization of siRNA-based lipid-lowering treatments, an increasing desire for cardiovascular therapies offering prolonged effects, a greater commitment to strategies in preventive cardiology, the broadening of sophisticated RNA manufacturing processes, and a reinforced emphasis on improving patient compliance.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=20143&type=smp

What Primary Drivers Are Shaping The Development Of The Leqvio Market?

The expanding geriatric demographic is anticipated to fuel the demand for leqvio in the future. This group comprises individuals typically 65 years and older, whose numbers are increasing due to notable progress in healthcare and medical technology, extending life expectancy. leqvio is particularly beneficial for older adults as it lowers LDL cholesterol, simplifying medication regimens, and its prolonged action mitigates cardiovascular risks, thereby improving health outcomes within this demographic. For instance, in January 2024, data from the Kenya-based nonprofit, Population Reference Bureau, indicated that the American population aged 65 and above is projected to surge from 58 million in 2022 to 82 million by 2050, representing a 47% rise. Concurrently, this age group’s proportion of the total population is also expected to climb from 17% to 23% over the identical timeframe. Consequently, the increasing geriatric population serves as a key impetus for the leqvio market’s expansion.

Which Segment Categories Define The Leqvio Market?

The leqvio market covered in this report is segmented –

1) By Formulation: Injectable Formulation (Subcutaneous), Pre-Filled Syringes Or Auto-Injectors

2) By Indication: Treatment Of Hyperlipidemia, Management Of Atherosclerotic Cardiovascular Disease (ASCVD), Treatment Of Familial Hypercholesterolemia

3) By Patient Demographics: Adult Patients, Geriatric Patients, Patients with Comorbid Conditions

4) By Distribution Channel: Direct Sales, Wholesalers and Distributors, Retail Pharmacies, Online Pharmacies

5) By End-User: Hospitals, Cardiovascular Clinics, Specialty Pharmacies, Home Healthcare Providers

What Major Market Trends Are Driving Changes In The Leqvio Market?

Leading companies active in the leqvio market are concentrating on developing advanced injectable prescription medications, such as those involving Label Expansion, to enhance therapeutic accessibility and facilitate early intervention. Label Expansion refers to the regulatory authorization granted by bodies, like the FDA, that permits an already approved drug to be used for additional indications, patient demographics, or clinical environments beyond its initial approved scope. For instance, in July 2023, Novartis AG, a Switzerland-based pharmaceutical company, received US Food and Drug Administration (FDA) approval for a label update for Leqvio (inclisiran), allowing its use at an earlier stage for patients with elevated LDL-C and an increased risk of heart disease, in addition to diet and statin therapy. Administered as two doses per year after two initial doses, it offers up to a 52% LDL-C reduction and has proven effective for patients unable to reach their LDL-C target despite statin therapy. This label update underscores robust safety and efficacy data, which was reinforced by the VictORION clinical trial program.

Who Are The Top Companies Competing In The Leqvio Market?

Major companies operating in the leqvio market are Novartis AG

Read the full leqvio market report here:

https://www.thebusinessresearchcompany.com/report/leqvio-global-market-report

How Does The Leqvio Market Perform Across Major Global Regions?

North America was the largest region in the leqvio market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the leqvio market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Leqvio Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=20143&type=smp

Browse Through More Reports Similar to the Global Leqvio Market 2026, By The Business Research Company

Inductor Market Market Report 2026

https://www.thebusinessresearchcompany.com/report/inductor-market-global-market-report

Vertical Market Software Market Report 2026

https://www.thebusinessresearchcompany.com/report/vertical-market-software-global-market-report

Data Lake Market Report 2026

https://www.thebusinessresearchcompany.com/report/data-lake-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795